The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...
Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...
This award, generously supported by the Brown Family from Atlanta, GA, is dedicated to pioneering research into the underlying mechanisms of non-small cell lung cancer (NSCLC) resistance to ...
Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, ...
AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...
The study, which is being conducted under an FDA-approved Investigational Device Exemption application, held by GRAIL, leverages GRAIL's targeted methylation platform to detect ctDNA. With GRAIL's ...
Radiopharm Theranostics has received approval from the Australian Ethics Committee for the inclusion of more tumour types ...
ArriVent BioPharma, Inc. ( (AVBP) ) has released its Q3 earnings. Here is a breakdown of the information ArriVent BioPharma, Inc. presented to ...
HotCopper.com on MSN9h
Radiopharm extends radioimmunotherapy trial to 5 more cancer typesRadiopharm Theranostics Ltd (ASX:RAD) has received approval from the Australian Ethics Committee to expand its trial to ...
If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.
The CHMP has recommended the Rybrevant-Lazcluze combination as a first-line treatment for adult patients with locally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback